The FDA announced a recall of Naloxone on Monday after the antidote's manufacturer flagged a potential issue with the syringe plunger. Hospira says that there is a low chance people will experience a wide range of adverse health effects but chose to recall the drug just in case.
See the full recall details.
US Food and Drug Administration. "DHHR is using a different brand of naloxone, Amphastar, which is not included in the FDA's recall of the brand Hospira".
Package labeling recommends visual inspection to detect the presence of discoloration or particulates before administration, which would diminish the risks for using these lots.More news: Apple pledges to cure your iPhone addiction
More news: Amazon breaks Premier League hold of Sky and BT with streaming deal
More news: Israel refused South Korea's request to publicly back Trump-Kim summit
This recall is only for Naloxone used in syringes, and not the nasal spray.
Naloxone is also available in the intravenous form, intramuscular, and subcutaneous.
When administered, naloxone quickly can restore normal respiration to someone whose breathing has slowed or stopped due to opioid use.
The voluntary recall by the Pfizer subsidiary is for Carpuject single-use cartridge syringe system (NDC 0409-1782-69) of naloxone hydrochloride injection, USP (lots 72680LL and 76510LL; 0.4 mg/mL, 1 mL in 2.5 mL doses for both lots).